Candriam S.C.A. Sells 48,363 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Candriam S.C.A. reduced its stake in Supernus Pharmaceuticals by 44.2%, selling 48,363 shares and retaining a total of 60,964 shares valued at approximately $1.997 million.
• Insider trading activity includes CEO Jack A. Khattar selling 140,000 shares for about $5.88 million, decreasing his ownership by 11.96%.
• Analysts' ratings for Supernus Pharmaceuticals have improved, with Wall Street Zen upgrading the stock to a "buy" and Cantor Fitzgerald raising the price target to $46.00.

Candriam S.C.A. cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 44.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,964 shares of the specialty pharmaceutical company's stock after selling 48,363 shares during the period. Candriam S.C.A. owned about 0.11% of Supernus Pharmaceuticals worth $1,997,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Supernus Pharmaceuticals by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock valued at $1,033,000 after purchasing an additional 1,083 shares during the last quarter. Two Sigma Advisers LP raised its stake in Supernus Pharmaceuticals by 14.7% during the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock worth $282,000 after acquiring an additional 1,000 shares in the last quarter. Principal Financial Group Inc. raised its stake in Supernus Pharmaceuticals by 3.2% during the first quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock worth $10,032,000 after acquiring an additional 9,590 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Supernus Pharmaceuticals by 6.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock valued at $2,169,000 after buying an additional 3,495 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of Supernus Pharmaceuticals by 63.6% in the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after buying an additional 6,867 shares during the period.

Supernus Pharmaceuticals Trading Down 0.2%

Shares of NASDAQ SUPN traded down $0.09 during midday trading on Friday, hitting $45.28. 78,409 shares of the company's stock were exchanged, compared to its average volume of 636,767. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $45.60. The company has a market cap of $2.54 billion, a price-to-earnings ratio of 39.35 and a beta of 0.74. The business's fifty day moving average price is $36.37 and its two-hundred day moving average price is $33.90.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on SUPN shares. Piper Sandler increased their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research report on Friday. Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Supernus Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $43.00.

Insider Activity at Supernus Pharmaceuticals

In other news, Director Bethany Sensenig sold 5,369 shares of the business's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.25, for a total transaction of $226,840.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jack A. Khattar sold 140,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total value of $5,882,800.00. Following the transaction, the chief executive officer directly owned 1,030,183 shares of the company's stock, valued at $43,288,289.66. The trade was a 11.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 179,606 shares of company stock valued at $7,617,005 in the last ninety days. Insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.